AB0 blood group and prognosis in patients with pancreatic cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Rahbari, Nuh N ^a   Bork, Ulrich ^a   Hinz, Ulf ^a   Leo, Albrecht ^a   Kirchberg, Johanna ^a   Koch, Moritz ^a   Büchler, Markus W ^a   Weitz, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864227854     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-319     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20(10):1218-1249. 10.1101/gad.1415606, 16702400.
3. Marcus DM. The ABO and Lewis blood-group system. Immunochemistry, genetics and relation to human disease. N Engl J Med 1969, 280(18):994-1006. 10.1056/NEJM196905012801806, 4888078.
4. Vogel F. Controversy in human genetics. ABO blood groups and disease. Am J Hum Genet 1970, 22(4):464-475. 1706590, 5432291.
5. Annese V, Minervini M, Gabbrielli A, Gambassi G, Manna R. ABO blood groups and cancer of the pancreas. Int J Pancreatol Off J Int Assoc Pancreatol 1990, 6(2):81-88.
6. Newell GR, Gordon JE, Monlezun AP, Horwitz JS. ABO blood groups and cancer. J Natl Cancer Inst 1974, 52(5):1425-1430.
7. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009, 41(9):986-990. 10.1038/ng.429, 2839871, 19648918.
8. Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, Giovannucci EL, Fuchs CS. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009, 101(6):424-431. 10.1093/jnci/djp020, 2657095, 19276450.
9. Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E, Stolzenberg-Solomon RZ, Arslan AA, Jacobs EJ, Lacroix A, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 2010, 70(3):1015-1023. 10.1158/0008-5472.CAN-09-2993, 2943735, 20103627.
10. Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer 2011, 128(5):1179-86. 10.1002/ijc.25426, 20473916.
11. Nakao M, Matsuo K, Hosono S, Ogata S, Ito H, Watanabe M, Mizuno N, Iida S, Sato S, Yatabe Y, et al. ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci 2011, 102(5):1076-1080. 10.1111/j.1349-7006.2011.01907.x, 21306478.
12. Gong Y, Yang YS, Zhang XM, Su M, Wang J, Han JD, Guo MZ. ABO blood type, diabetes and risk of gastrointestinal cancer in northern China. World J Gastroenterol: WJG 2012, 18(6):563-569. 10.3748/wjg.v18.i6.563, 3280403, 22363124.
13. Dandona M, Gao F, Linehan DC, Wang-Gillam A. Re: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2010, 102(2):135-137. 10.1093/jnci/djp447, 20019335.
14. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol 2006, 24(18):2897-2902.
15. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004, 11(7):644-649. 10.1245/ASO.2004.11.025, 15197014.
16. Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol Off J Am Soc Clin Oncol 2008, 26(36):5918-5922.
17. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008, 9(2):132-138. 10.1016/S1470-2045(08)70001-9, 18249033.
18. Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, Barone C, Rosbrook B, Ricart AD, Kim S, Spano JP. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer Suppl 2009, 101(7):1162-1167.
19. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979, 5(6):957-971. 10.1007/BF01542654, 94699.
20. Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk M, Mitchell KF, Steplewski Z, Koprowski H. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science (New York, NY) 1981, 212(4490):55-56.
21. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983, 29(3):549-552.
22. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer Suppl 1986, 53(2):197-202.
23. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Mäkelä O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984, 37(2):218-222. 10.1136/jcp.37.2.218, 498681, 6198342.
24. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363(9414):1049-1057. 10.1016/S0140-6736(04)15841-8, 3062508, 15051286.
25. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochimica Et Biophysica Acta 1999, 1473(1):247-266. 10.1016/S0304-4165(99)00183-X, 10580143.
26. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clément M. ABH and Lewis histo-blood group antigens in cancer. APMIS: Acta Pathologica, Microbiologica, Et Immunologica Scandinavica 2001, 109(1):9-31. 10.1111/j.1600-0463.2001.tb00011.x, 11297197.
27. ochler MW. The "artery first" approach for resection of pancreatic head cancer. J Am Coll Surg 2010, 210(2):e1-4.
28. ochler MW. Portal vein resection for advanced pancreatic head cancer. J Am Coll Surg 2007, 204(4):712-716. 10.1016/j.jamcollsurg.2007.01.004, 17382233.
29. ochler MW. Surgical resection for pancreatic cancer. Pancreatic Cancer. edn 2010, 971-976. Berlin: Springer.
30. ochler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008, 15(6):1651-1660. 10.1245/s10434-008-9839-8, 18351300.
31. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. The Journal of Pathology 1996, 179(4):358-369. 10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T, 8869281.
32. Krause T, Turner GA. Are selectins involved in metastasis?. Clin Exp Metastasis 1999, 17(3):183-192. 10.1023/A:1006626500852, 10432003.
33. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004, 95(5):377-384. 10.1111/j.1349-7006.2004.tb03219.x, 15132763.
34. Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, Chen J, Kobayashi M, Hosokawa M, Taniguchi A, et al. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(21):8132-8137. 10.1073/pnas.0402088101, 419569, 15141079.
35. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993, 53(2):354-361.
36. Tei K, Kawakami-Kimura N, Taguchi O, Kumamoto K, Higashiyama S, Taniguchi N, Toda K, Kawata R, Hisa Y, Kannagi R. Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats. Cancer Res 2002, 62(21):6289-6296.
37. Holdsworth PJ, Thorogood J, Benson EA, Clayden AD. Blood group as a prognostic indicator in breast cancer. Br Med J (Clinical Research Ed) 1985, 290(6469):671-673.
38. Wolf GT, Carey TE, Schmaltz SP, McClatchey KD, Poore J, Glaser L, Hayashida DJ, Hsu S. Altered antigen expression predicts outcome in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1990, 82(19):1566-1572. 10.1093/jnci/82.19.1566, 2119437.
39. Nakagoe T, Nanashima A, Sawai T, Tuji T, Ohbatake M, Jibiki M, Yamaguchi H, Yasutake T, Ayabe H, Matuo T, et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. J Cancer Res Clin Oncol 2000, 126(7):375-382. 10.1007/PL00008485, 10929759.
40. Nakagoe T, Fukushima K, Itoyanagi N, Ikuta Y, Oka T, Nagayasu T, Ayabe H, Hara S, Ishikawa H, Minami H. Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 2002, 128(5):257-264. 10.1007/s00432-002-0334-5, 12029441.
41. Sv M, Le Moullac-Vaidye B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology 2002, 12(12):851-856. 10.1093/glycob/cwf103, 12499407.
42. Paré G, Chasman DI, Kellogg M, Zee RYL, Rifai N, Badola S, Miletich JP, Ridker PM. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 2008, 4(7):e1000118. 10.1371/journal.pgen.1000118, 2432033, 18604267.
43. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 2004, 15(2):91-98.
44. ock W, Wöckel L, Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 1995, 60(1-2):9-15.
45. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867. 10.1038/nature01322, 2803035, 12490959.
46. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444. 10.1038/nature07205, 18650914.
47. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007, 14(4):377-386. 10.2174/092986707779941032, 17305540.
48. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002, 12(2):89-96. 10.1006/scbi.2001.0416, 12027580.